FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283272934> ?p ?o ?g. }

• W4283272934 endingPage "100668" @default.
• W4283272934 startingPage "100668" @default.
• W4283272934 abstract "In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.1Cortés J. Kim S.-B. Chung W.-P. Kim S.-A. Park Y.H. Hegg R. et al.Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N. Engl. J. Med. 2022; 386: 1143-1154https://doi.org/10.1056/NEJMOA2115022/SUPPL_FILE/NEJMOA2115022_DATA-SHARING.PDFCrossref PubMed Scopus (0) Google Scholar This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer. In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.1Cortés J. Kim S.-B. Chung W.-P. Kim S.-A. Park Y.H. Hegg R. et al.Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N. Engl. J. Med. 2022; 386: 1143-1154https://doi.org/10.1056/NEJMOA2115022/SUPPL_FILE/NEJMOA2115022_DATA-SHARING.PDFCrossref PubMed Scopus (0) Google Scholar This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer. Despite numerous successes in the history of medical oncology, few have rivaled the metamorphosis that took place in breast cancer with the discovery of the HER2 gene and its subsequent targeting with trastuzumab. In 1987, Slamon and colleagues published the first clinical data of a novel gene called errb2, or HER2/neu, and significantly worse relapse-free survival and overall survival in patients with HER2-amplified breast cancer.2Slamon D.J. Clark G.M. Wong S.G. Levin W.J. Ullrich A. Mcguire W.L. Human breast cancer: Correlation of relapse and survival with Amplification of the HER-2/neu oncogene.New Ser. 1987; 235: 177-182https://doi.org/10.1126/science.3798106Crossref Scopus (9726) Google Scholar Subsequent laboratory-based studies elucidated HER2’s role as a driver oncogene linked to aggressive tumor behavior. This was followed by the development of trastuzumab, a humanized anti-HER2 monoclonal antibody (mAb), that improved progression-free survival (PFS) and overall survival when combined with chemotherapy for HER2-overexpressed (HER2+) metastatic breast cancer (MBC)3Slamon D.J. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bajamonde A. Fleming T. Eiermann W. Wolter J. Pegram M. et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that Overexpresses HER2.N. Engl. J. Med. 2001; 344: 783-792https://doi.org/10.1056/nejm200103153441101Crossref PubMed Scopus (0) Google Scholar and early-stage breast cancer,4Perez E.A. Romond E.H. Suman V.J. Jeong J.H. Sledge G. Geyer Jr., C.E. Martino S. Rastogi P. Gralow J. Swain S.M. et al.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.J. Clin. Oncol. 2014; 32: 3744-3752https://doi.org/10.1200/JCO.2014.55.5730Crossref PubMed Scopus (590) Google Scholar cementing it as a core treatment and laying the foundation for several further advances in HER2-targeting approaches, including tyrosine-kinase inhibitors (TKIs), novel mAbs, and most recently, antibody-drug conjugates (ADCs). One such ADC, fam-trastuzumab deruxtecan (T-DXd), has recently been shown to prolong PFS compared with trastuzumab emtansine (T-DM1) in HER2+ MBC in the international phase 3 randomized clinical trial DESTINY-Breast 03 (DB-03), the focus of this spotlight, reported by Cortés et al.1Cortés J. Kim S.-B. Chung W.-P. Kim S.-A. Park Y.H. Hegg R. et al.Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N. Engl. J. Med. 2022; 386: 1143-1154https://doi.org/10.1056/NEJMOA2115022/SUPPL_FILE/NEJMOA2115022_DATA-SHARING.PDFCrossref PubMed Scopus (0) Google Scholar DB-03 enrolled HER2+ MBC patients previously progressing on taxane and trastuzumab (median 1–2 prior lines of therapy) and randomized to T-DXd versus T-DM1. Importantly, 62% of participants had prior pertuzumab, 50% were ER+, 70% had visceral metastases, and roughly 20% had stable brain metastases at enrollment. Despite this study being positioned in the “second-line” setting given the current indication for T-DM1, the ranges of prior lines of therapy were 0–16 for T-DXd and 0–14 for T-DM1, which the authors cite as due to limited availability of T-DM1 in certain countries participating in this study. With these characteristics in mind, the median PFS (mPFS) was not reached for T-DXd versus 6.8 months for T-DM1, representing a 72% improvement in PFS, with 12-month PFS rates of 75.8% and 34.1%, respectively. Equally impressive, the disease control rate, defined as partial response, complete response, or stable disease for ≥6 months, was 96.6% (T-DXd) versus 76.8% (T-DM1). All key subgroups favored T-DXd. Additional data presented at the San Antonio Breast Cancer Symposium (SABCS) in 2021 regarding participants with stable brain metastases at enrollment demonstrated a clinically significant improvement in mPFS (15 months T-DXd versus 3 months T-DM1) and intracranial objective response rates (63.9% versus 33.4%, respectively), suggesting that T-DXd crosses the blood-brain barrier.5Hurvitz S. Kim S.-B. Chung W.-P. Im S.-A. Park Y.H. Hegg R. Kim M.-H. Tseng L.-M. Petry V. Chung C.-F. et al.Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer. 2021 San Antonio Breast Cancer Symposium.in: SABCS 2021. 2021Google Scholar These data led to an updated NCCN recommendation for T-DXd as the preferred second-line therapy with category one evidence, and on May 4th, 2022, the FDA granted regular approval in this setting, making this a new standard second-line therapy for HER2+ MBC. T-DXd represents an advancement in the evolution of ADCs, all of which comprise three critical components that contribute to therapeutic index: the antigen-specific antibody (necessary for tumor-antigen targeting and stimulating immune response), the cytotoxic drug (termed “payload”), and the linker that joins the two (important for keeping the payload attached to the antibody until final delivery into the target cell). Design nuances in each component influence the balance between efficacy and toxicity. T-DXd’s combination of a high drug-antibody ratio (DAR) of eight molecules per antibody, plasma-stable linker that is selectively cleaved by tumor lysosomal proteases, and membrane-permeable payload (able to diffuse out into neighboring cells, thereby addressing tumor heterogeneity with a “bystander” effect) has led to impressive response rates in various HER2-expressing cancers including breast, lung, and gastric tumors. T-DXd first demonstrated activity in a phase 1, multi-cohort, dose-expansion study of heavily pre-treated patients with HER2+ MBC, demonstrating an objective response rate (ORR) 59.5% and median duration of response of 20.7 months6Tamura K. Tsurutani J. Takahashi S. Iwata H. Krop I.E. Redfern C. Sagara Y. Doi T. Park H. Murthy R.K. et al.Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.Lancet Oncol. 2019; 20: 816-826https://doi.org/10.1016/S1470-2045(19)30097-XAbstract Full Text Full Text PDF PubMed Scopus (144) Google Scholar These data led to the single arm phase 2 registration study DB-01, testing T-DXd in a similar population (median seven prior lines of therapy) which yielded a 60.9% ORR and an mPFS of 16.4 months7 Based on these results, the FDA granted T-DXd accelerated approval in 2019 for patients with HER2+ MBC having progressed on T-DM1. Given its bystander effect, T-DXd was also tested in a cohort of participants with HER2- (by FISH) MBC with HER2 1+/2+ expression by immunohistochemistry (HER2 low), a population for which anti-HER2 therapy had historically not been effective, demonstrating an ORR of 37% and median duration of response of 10.4 months7Modi S. Park H. Murthy R.K. Iwata H. Tamura K. Tsurutani J. Moreno-Aspitia A. Doi T. Sagara Y. Redfern C. et al.Antitumor activity and Safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study.J. Clin. Oncol. 2020; 38: 1887-1896https://doi.org/10.1200/JCO.19.02318Crossref PubMed Scopus (173) Google Scholar These data provided rationale for DB-04, a randomized phase 3 trial evaluating T-DXd versus physician’s choice for HER2 low tumors, the results of which were announced in a recent press release8Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improves-pfs-and-os-in-her2-low-bc.htmlGoogle Scholar indicating that PFS and overall survival (OS) endpoints had been met and thus potentially adding T-DXd and other ADCs with bystander effect as additional agents for triple-negative and ER+ breast cancers with low-intermediate expression of HER2. The initial successes of T-DXd were tempered, however, by a signal for high-grade interstitial lung disease (ILD)/pneumonitis. In the phase 2 DB-01 trial, 13.6% of participants developed any-grade ILD, and 4 participants (2.2%) died from ILD.9Modi S. Saura C. Yamashita T. Park Y.H. Kim S.-B. Tamura K. et al.Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.N. Engl. J. Med. 2020; 382: 610-621https://doi.org/10.1056/NEJMOA1914510/SUPPL_FILE/NEJMOA1914510_DATA-SHARING.PDFCrossref PubMed Scopus (0) Google Scholar As a result of this early experience, institution of rigorous monitoring for signs and symptoms of ILD, as well as early drug interruption and steroid initiation for any-grade ILD or grade ≥2 pneumonitis, has led to lowered rates of ILD and no further grade 5 events. In DB-03, there were only 0.8% G3 events and no ILD-related deaths.1Cortés J. Kim S.-B. Chung W.-P. Kim S.-A. Park Y.H. Hegg R. et al.Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N. Engl. J. Med. 2022; 386: 1143-1154https://doi.org/10.1056/NEJMOA2115022/SUPPL_FILE/NEJMOA2115022_DATA-SHARING.PDFCrossref PubMed Scopus (0) Google Scholar Additional frequent toxicities noted with T-DXd in DB-03 included high rates of G ≥ 3 myelosuppression (including neutropenia [19%], anemia [5.8%], thrombocytopenia [7.8%]), nausea (6.6%), and fatigue (5.1%), a reminder that off-target toxicity remains a challenge for the “targeted” chemo approach of ADCs. As the field of ADCs continues to grow, several key questions remain, including: what is the optimal sequencing of ADCs in the metastatic setting, and what role will ADCs in the neo- and post-neoadjuvant setting for early stage breast cancer play (under investigation in the DB-05 study evaluating T-DXd versus T-DM1 in HER2+ breast cancer with residual disease after neoadjuvant therapy10Geyer C.E. Untch M. Prat A. Rastogi P. Niikura N. Mathias E. et al.Abstract OT-03-01: trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05).Cancer Res. 2021; 81 (OT-03-01)https://doi.org/10.1158/1538-7445.SABCS20-OT-03-01Crossref Google Scholar)? Given its toxicity, strategies for selecting patients most likely to benefit are key. Doing so could provide an opportunity to investigate new biomarkers, including those based on radiomics utilizing novel HER2-tracers, for in vivo assessment of target expression. Further advances in ADC technology, such as dual payloads, novel synthetic site-specific payload conjugation, and targeting of the tumor microenvironment in addition to the tumor antigen, will hopefully continue to improve efficacy and widen the therapeutic window. The publication of DB-03 both commemorates the past successes of trastuzumab-based targeting for HER2+ breast cancer and looks forward to the next 5–10 years, which will no doubt see continued advancements in ADC technology. With 11 currently approved ADCs and several more under development, it appears we have reached another metamorphosis in oncology. The authors declare no competing interests." @default.
• W4283272934 created "2022-06-23" @default.
• W4283272934 creator A5005537242 @default.
• W4283272934 creator A5013270754 @default.
• W4283272934 date "2022-06-01" @default.
• W4283272934 modified "2023-09-25" @default.
• W4283272934 title "Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer" @default.
• W4283272934 cites W1996778928 @default.
• W4283272934 cites W2141393790 @default.
• W4283272934 cites W2318605753 @default.
• W4283272934 cites W2942867242 @default.
• W4283272934 cites W2996630100 @default.
• W4283272934 cites W3005585857 @default.
• W4283272934 cites W4226051140 @default.
• W4283272934 doi "https://doi.org/10.1016/j.xcrm.2022.100668" @default.
• W4283272934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35732147" @default.
• W4283272934 hasPublicationYear "2022" @default.
• W4283272934 type Work @default.
• W4283272934 citedByCount "2" @default.
• W4283272934 countsByYear W42832729342022 @default.
• W4283272934 countsByYear W42832729342023 @default.
• W4283272934 crossrefType "journal-article" @default.
• W4283272934 hasAuthorship W4283272934A5005537242 @default.
• W4283272934 hasAuthorship W4283272934A5013270754 @default.
• W4283272934 hasBestOaLocation W42832729342 @default.
• W4283272934 hasConcept C121608353 @default.
• W4283272934 hasConcept C126322002 @default.
• W4283272934 hasConcept C127413603 @default.
• W4283272934 hasConcept C134306372 @default.
• W4283272934 hasConcept C143998085 @default.
• W4283272934 hasConcept C146978453 @default.
• W4283272934 hasConcept C159654299 @default.
• W4283272934 hasConcept C197336794 @default.
• W4283272934 hasConcept C203014093 @default.
• W4283272934 hasConcept C2777325958 @default.
• W4283272934 hasConcept C2779786085 @default.
• W4283272934 hasConcept C2780035454 @default.
• W4283272934 hasConcept C33923547 @default.
• W4283272934 hasConcept C44761211 @default.
• W4283272934 hasConcept C502942594 @default.
• W4283272934 hasConcept C530470458 @default.
• W4283272934 hasConcept C542903549 @default.
• W4283272934 hasConcept C71924100 @default.
• W4283272934 hasConcept C98274493 @default.
• W4283272934 hasConceptScore W4283272934C121608353 @default.
• W4283272934 hasConceptScore W4283272934C126322002 @default.
• W4283272934 hasConceptScore W4283272934C127413603 @default.
• W4283272934 hasConceptScore W4283272934C134306372 @default.
• W4283272934 hasConceptScore W4283272934C143998085 @default.
• W4283272934 hasConceptScore W4283272934C146978453 @default.
• W4283272934 hasConceptScore W4283272934C159654299 @default.
• W4283272934 hasConceptScore W4283272934C197336794 @default.
• W4283272934 hasConceptScore W4283272934C203014093 @default.
• W4283272934 hasConceptScore W4283272934C2777325958 @default.
• W4283272934 hasConceptScore W4283272934C2779786085 @default.
• W4283272934 hasConceptScore W4283272934C2780035454 @default.
• W4283272934 hasConceptScore W4283272934C33923547 @default.
• W4283272934 hasConceptScore W4283272934C44761211 @default.
• W4283272934 hasConceptScore W4283272934C502942594 @default.
• W4283272934 hasConceptScore W4283272934C530470458 @default.
• W4283272934 hasConceptScore W4283272934C542903549 @default.
• W4283272934 hasConceptScore W4283272934C71924100 @default.
• W4283272934 hasConceptScore W4283272934C98274493 @default.
• W4283272934 hasIssue "6" @default.
• W4283272934 hasLocation W42832729341 @default.
• W4283272934 hasLocation W42832729342 @default.
• W4283272934 hasLocation W42832729343 @default.
• W4283272934 hasOpenAccess W4283272934 @default.
• W4283272934 hasPrimaryLocation W42832729341 @default.
• W4283272934 hasRelatedWork W1722328147 @default.
• W4283272934 hasRelatedWork W2066747782 @default.
• W4283272934 hasRelatedWork W2461520869 @default.
• W4283272934 hasRelatedWork W2593475799 @default.
• W4283272934 hasRelatedWork W2934076975 @default.
• W4283272934 hasRelatedWork W4214766446 @default.
• W4283272934 hasRelatedWork W4231523912 @default.
• W4283272934 hasRelatedWork W4239568381 @default.
• W4283272934 hasRelatedWork W4322772378 @default.
• W4283272934 hasRelatedWork W2342209702 @default.
• W4283272934 hasVolume "3" @default.
• W4283272934 isParatext "false" @default.
• W4283272934 isRetracted "false" @default.
• W4283272934 workType "article" @default.